Unum Therapeutics Inc (NASDAQ:UMRX) Receives Average Rating of “Buy” from Analysts

Unum Therapeutics Inc (NASDAQ:UMRX) has been assigned an average rating of “Buy” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $14.60.

UMRX has been the topic of a number of research reports. SunTrust Banks dropped their target price on Unum Therapeutics to $10.00 and set a “buy” rating on the stock in a report on Friday, March 29th. They noted that the move was a valuation call. Zacks Investment Research downgraded Unum Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, April 17th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Unum Therapeutics in a report on Friday, March 29th. Finally, Cowen initiated coverage on Unum Therapeutics in a report on Tuesday, February 26th. They issued a “market perform” rating on the stock.

Shares of UMRX opened at $2.71 on Thursday. The stock has a market capitalization of $87.95 million, a PE ratio of -1.95 and a beta of 1.75. Unum Therapeutics has a fifty-two week low of $2.73 and a fifty-two week high of $17.66. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.65 and a current ratio of 2.65.

Unum Therapeutics (NASDAQ:UMRX) last issued its earnings results on Monday, May 13th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). The business had revenue of $3.05 million during the quarter, compared to analyst estimates of $3.15 million. Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%. On average, sell-side analysts expect that Unum Therapeutics will post -1.35 EPS for the current fiscal year.

In related news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $4.12, for a total value of $47,318.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Several hedge funds and other institutional investors have recently made changes to their positions in UMRX. Vanguard Group Inc. grew its stake in shares of Unum Therapeutics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 552,380 shares of the company’s stock valued at $5,690,000 after buying an additional 22,510 shares in the last quarter. BlackRock Inc. boosted its position in Unum Therapeutics by 281.5% during the fourth quarter. BlackRock Inc. now owns 1,530,419 shares of the company’s stock worth $6,733,000 after purchasing an additional 1,129,262 shares during the period. Bank of New York Mellon Corp boosted its position in Unum Therapeutics by 251.5% during the fourth quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock worth $204,000 after purchasing an additional 33,091 shares during the period. Northern Trust Corp boosted its position in Unum Therapeutics by 312.6% during the fourth quarter. Northern Trust Corp now owns 178,640 shares of the company’s stock worth $786,000 after purchasing an additional 135,345 shares during the period. Finally, Sectoral Asset Management Inc boosted its position in Unum Therapeutics by 19.4% during the fourth quarter. Sectoral Asset Management Inc now owns 1,250,145 shares of the company’s stock worth $5,501,000 after purchasing an additional 203,200 shares during the period. 47.27% of the stock is owned by institutional investors and hedge funds.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

Read More: Elliott Wave Theory

Analyst Recommendations for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply